
Class II / De Novo
SaMD & Digital Health
Software classification, clinical validation and pathways for connected and AI-enabled devices.
CAHIR MedTech builds AI workspaces that help MedTech teams move their ideas from initial concepts to working prototypes more predictably and drive strategic growth faster with actionable and defensible market intelligence.
Most MedTech teams face two disconnected questions: where to launch and how to get regulatory-ready. CAHIR's AI products answer both in connected workspaces.
Strategy
Compliance
Open-source
News, insights, toolkits, guidance, and everything in between to help innovators succeed in MedTech

Understand CMS’s NTAP cost criterion, standardized charges, MS-DRG selection and CCR assumptions. Start with the free check, then model scenarios and export an executive brief with NTAP Analyzer.
Read article
Understand hospital inpatient device reimbursement, MS-DRG economics, CCR assumptions and NTAP limits before a CFO or value-analysis meeting. Start with the free threshold check, then document cost-criterion scenarios with NTAP Analyzer.
Read article
New to NTAP? Learn how Medicare’s temporary inpatient add-on payment works, who receives it, the eligibility criteria, application process and limits—and where founders can start.
Read articleA continuous lifecycle for founders and innovators. Jump in at any stage, and come back around whenever you have new questions.
Your device lifecycle
DevicePath
Phase 1 of 4
Phase 1 · DevicePath
Describe your device and get its likely FDA class, candidate product codes, probable pathway and real 510(k) predicate candidates.
Highly recommended: Go deeper with the MedCompass Premium Regulatory Analyzer for a pathway analysis built on vetted sources.
What you get
Not sure where to begin? Contact our team at medtech@cahir.ai — we bring decades of medtech commercialization experience to every engagement.
Services included with your engagement
Four advisory stages our experts and partners walk through with you, from the first clinical signal to successful market integration.
The pathway closes where it matters — approval, coverage, adoption, and revenue: successful market integration.
From implantable devices to digital health, connect regulatory development with market access through MedTech Copilot and MedTech Compass.

Class II / De Novo
Software classification, clinical validation and pathways for connected and AI-enabled devices.

510(k) / De Novo
Predicate assessment, analytical performance and clinical evidence for diagnostic technologies.

Class III / PMA
Evidence planning, risk management and premarket approval strategy for high-risk implants.
Orthopedic device pathway
Imaging / Robotics
Regulatory strategy, hospital purchasing and total-cost-of-ownership insights for major systems.

High Volume
Device-specific pathways, procurement economics and adoption planning for high-volume products.

Drug–device combination products
Primary mode of action, constituent-part requirements and evidence planning for drug–device combination products.
Categories illustrate areas of support, not fixed classifications. The applicable FDA class and pathway depend on intended use, risk and available predicates; De Novo generally establishes Class I or II classification. Combination-product jurisdiction and requirements depend on the primary mode of action and constituent parts.
Development engine
Requirements, design history and quality documentation, structured for regulatory readiness.
Intelligence engine
Pathways, reimbursement, competition and market opportunity, prioritized for adoption.
Shared evidence foundation
Built for informed decisions you can trust and verify. Outputs support expert review; they do not replace regulatory, clinical or reimbursement advice.
The Cahir MedTech Workspace brings your toolkits, checklists, notes and team history together on one screen, so regulatory and quality work moves forward in one place.
Every toolkit your company has unlocked, in one shared place for the whole team.
Work through each toolkit item by item and see progress update for everyone.
Leave notes on any item so reviewers and auditors see the context behind the work.
See who changed what and when. Every name and time is recorded automatically.
Sign up with a password or a one-click email link. No password needed if you prefer.
We create your company workspace automatically from your email domain.
Teammates with the same work email domain land in the same workspace.
Market reality
Bringing a device to market takes years and serious capital, and every step needs evidence. Here is what founders are up against, and where Cahir helps.

Development timeline
Years
Hover or tap for details
Development timeline
Years
Concept to U.S. market takes years, and longest for PMA devices that need clinical studies
Source: Makower et al., Stanford (2010)With Cahir
Pathway and predicate triage up front so teams don't take the wrong route.

Capital required
$31M / $94M
Hover or tap for details
Capital required
$31M / $94M
Average cost from concept to market: 510(k) vs. PMA devices
Source: Makower et al., Stanford (2010)With Cahir
Structured evidence drafting cuts down rework between milestones.

Review deficiencies
Clock stops
Hover or tap for details
Review deficiencies
Clock stops
FDA Additional Information requests put the 510(k) review on hold until a full response arrives
Source: FDA guidance: Types of Communication During ReviewWith Cahir
eSTAR readiness checklists and toolkits to find gaps before you submit.

Reimbursement lag
≤5 / yr
Hover or tap for details
Reimbursement lag
≤5 / yr
Breakthrough devices CMS will accept each year into its TCET expedited coverage pathway
Source: CMS TCET final notice (2024)With Cahir
Global market and reimbursement mapping from early in development.
Pick a challenge to see how Cahir helps.
Funding gaps between proof-of-concept, verification and clinical milestones.
How Cahir accelerates the crossing
Our five-phase framework helps health systems, buyers and partners evaluate AI-enabled medical devices before capital is committed, then oversee them after go-live.
5
Advisory phases
40/35/25
Clinical · technical · operational
100
Point Procurement Readiness Score

New FDA authorizations from the AI-Enabled Medical Devices list and radiology AI news from RadAISlice — each linking to the full original record or article.
Announcements, safety alerts and reimbursement news from the agencies that decide your route to market — collected automatically and filterable by date.
One framework built on vetted sources, tailored to every seat at the table.
Clarify whether your innovation solves a validated, reimbursable, and adoptable problem before costly downstream execution.
Start a conversationEvaluate new device opportunities through workflow fit, total cost of ownership, reimbursement feasibility, and implementation readiness.
Start a conversationBuild stronger launch plans, evidence narratives, and adoption strategies that work across procurement, clinical champions, and payers.
Start a conversationUse a repeatable diligence and readiness framework to identify whether a solution is technically promising and commercially viable.
Start a conversationExplore 103 terms across development, manufacturing, supply chains, clinical evidence and commercialization — with primary sources.
Device category
103 relevant terms · Cross-device topics included
Popular terms
Predetermined Change Control Plan
A Predetermined Change Control Plan (PCCP) is the part of a marketing submission that describes planned device modifications, how they will be developed and validated, and their impact assessment, so authorized changes can be made without a new submission.
Why it matters for founders
For AI/ML devices, an authorized PCCP lets you update models faster — but every change must still be executed under your quality system.
Related terms
AI/ML PCCP Suite
$399 USD · One-time · Applicable taxes may apply
One security foundation. Every product.
Your strategy, design records and market intelligence stay yours.

Hosted on cloud infrastructure that maintains SOC 2 Type II and ISO 27001:2022 certifications.
Row Level Security scopes every record to your organization. No cross-tenant access, by policy and by design.
Payments processed by Stripe (PCI-DSS Level 1). Card and bank details never touch CAHIR servers.













